Clinical Trial Update: Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care [Phase 1]

View source ↗

Summary

This update reports the completion of a multi-centre Phase 1 trial evaluating HTL0018318 as an add-on to standard of care in Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• HTL0018318 (HTL0018318)

Snippet

Sponsor: Nxera Pharma UK Limited | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED